Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS

Besides Wall Street's top-and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

Zacks Investment Research • Feb 20, 2026

Ionis to present at upcoming investor conferences

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Virtual Conference on Thursday, February 26, 2026 TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 Leerink Global Healthcare Conference on Monday, March 9, 2026 Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 Stifel.

Business Wire • Feb 19, 2026

Ionis updates time for fourth quarter and full year 2025 financial results webcast

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live webcast, previously scheduled for 11:30 a.m. Eastern Time, will now be held at 8:30 a.m. Eastern Time on Wednesday, February 25. The date of the call remains unchanged. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limi.

Business Wire • Feb 17, 2026

Ionis to hold fourth quarter and full year 2025 financial results webcast

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades.

Business Wire • Feb 11, 2026

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 11, 2026

Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema

IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.

Zacks Investment Research • Jan 22, 2026

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA™ (donidalorsen) in the European Union (EU) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The approval follows the positive opinion of the Committee for Medicinal Products for Human Use. The approval is based on positive.

Business Wire • Jan 21, 2026

Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth

Ionis Pharmaceuticals (IONS) has appreciated ~25% since my last upgrade, reflecting strong momentum. This article spotlights Olezarsen, Ionis's wholly owned molecule, as a key driver of future upside. Recent approvals and upcoming catalysts underpin the bullish investment thesis for IONS.

Seeking Alpha • Jan 20, 2026

Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected in 2026. Ionis will provide a business update at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 8:15am PT; the presentation is available today on the Ionis website here. “2025 was a defining year for Ionis, as we successfully executed our first two independent launches.

Business Wire • Jan 12, 2026